James Greer, MD
Psychiatry · Providence, RINPI 1548268303
Payments from drug & device makers
Across 1,001 payments — averaging $779.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$215K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$124K
- E.r. Squibb & Sons, L.L.C.$104K
- Neurocrine Biosciences, Inc.$85K
- Teva Pharmaceuticals USA, Inc.$84K
- AbbVie$66K
- plus $103K from 13 others
What the payments were for
- Consulting fees$65,2068%
- Speaking & faculty fees$632,07981%
- Travel & lodging$49,7336%
- Food & beverage$33,0494%
- Education$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 203 | $214,579 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 137 | $123,573 |
| E.r. Squibb & Sons, L.L.C. | 116 | $104,191 |
| Neurocrine Biosciences, Inc. | 94 | $84,714 |
| Teva Pharmaceuticals USA, Inc. | 99 | $84,000 |
| AbbVie(2 entities) | 182 | $66,318 |
| Vanda Pharmaceuticals Inc. | 73 | $62,546 |
| Sunovion Pharmaceuticals Inc. | 29 | $20,210 |
| Idorsia Pharmaceuticals US Inc | 7 | $9,792 |
| Supernus Pharmaceuticals, Inc. | 30 | $8,202 |
| Axsome Therapeutics, Inc. | 6 | $540 |
| Otsuka America Pharmaceutical, Inc. | 9 | $469 |
| Ironshore Pharmaceuticals Inc. | 2 | $397 |
| Corium, LLC | 3 | $318 |
| Evolution Surgical, Inc | 1 | $100 |
| Indivior Inc. | 3 | $68 |
| Shire North American Group Inc | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $42 |
| Johnson & Johnson | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$780,129 in reported general payments places this provider in the 95th percentile of 209 psychiatry providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 100 | $344,959 |
| Invega TrinzaPaliperidone Palmitate | 31 | $314,474 |
| IngrezzaValbenazine Tosylate | 37 | $300,838 |
| UzedyRisperidone | 30 | $130,548 |
| CaplytaLumateperone Tosylate | 60 | $94,429 |
| VraylarCariprazine Hcl | 43 | $73,025 |
| LybalviOlanzapine/Samidorphan Malate | 24 | $35,008 |
| CobenfyXanomeline Tart/Trospium Chlor | 16 | $25,859 |
| Paliperidone ErPaliperidone | 70 | $22,018 |
| Clozapine | 159 | $19,124 |
| QuviviqDaridorexant Hcl | 27 | $13,558 |
| TrintellixVortioxetine Hydrobromide | 21 | $9,998 |
| Olanzapine | 241 | $9,350 |
| Quetiapine Fumarate | 179 | $5,634 |
| Hydroxyzine Hcl | 182 | $5,606 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $17 | $659,433131 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $84,714 | $300,83837 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $84,000 | $130,54830 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $123,573 | $94,42960 claims |
| AbbVieVraylar | $66,318 | $73,02543 claims |
| Alkermes, Inc.Lybalvi | $214,579 | $35,00824 claims |
| E.r. Squibb & Sons, L.L.C.Cobenfy | $104,191 | $25,85916 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $9,792 | $13,55827 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $42 | $9,99821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 209 psychiatry providers in Rhode Island.
Other psychiatry in Providence
- Linda CarpenterProvidence$393K
- Paul WallaceProvidence$21K
- Teri PearlsteinProvidence$19K
- David KahnProvidence$18K
- Steven RasmussenProvidence$6K
- Kazi SalahuddinProvidence$4K
- Edward HueyProvidence$3K
- Marygene Santa TeresaProvidence$3K
- Kathryn Erickson-RidoutProvidence$2K
- Laura MayerProvidence$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.